Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice

被引:63
作者
Coulfield, Michael J.
Shi, Li
Wang, Su
Wang, Bei
Tobery, Timothy W.
Mach, Henryck
Ahl, Patrick L.
Cannon, Jayme L.
Cook, James C.
Heinrichs, Jon H.
Sitrin, Robert D.
机构
[1] Merck Res Labs, Vaccine & Biol Res, West Point, PA 19486 USA
[2] Merck Res Labs, Vaccine Pharmaceut Res, West Point, PA 19486 USA
[3] Merck Res Labs, Bioproc & Bioanalyt Res, West Point, PA 19486 USA
来源
HUMAN VACCINES | 2007年 / 3卷 / 04期
关键词
HPV; vaccine; aluminum adjuvant;
D O I
10.4161/hv.3.4.4309
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Aluminum adjuvants are commonly used in prophylactic vaccines to enhance antigen immunogenicity through induction of high-titer antibody responses. Three major forms of aluminum adjuvants with substantially different physical and chemical properties have been described: aluminum phosphate (AlPO4), aluminum hydroxide (AIOH) and amorphous aluminum hydroxyphosphate sulfate (AAHS). Here we describe the effect of these different aluminum adjuvants on the formulation and subsequent immunogenicity in mice of virus-like particles (VLPs) consisting of the L1 protein of Human Papillomovirus (HPV) Type 16. Electron microscopy demonstrated that the physical appearance of the phosphate-containing aluminum adjuvants was markedly different from that of aluminum hydroxide. All three aluminum adjuvants were found to display unique surface charge profiles over a range of pH, while AAHS demonstrated the greatest inherent capacity for adsorption of L1 VLPs. These differences were associated with differences in immunogenicity: anti-HPV L1 VLP responses from mice immunized with AAHS-formulated HPV16 vaccine were substantially greater than those produced by mice immunized with the same antigen formulated with aluminum hydroxide. In addition, HPV L1 VLPs formulated on AAHS also induced a substantial interferon-gamma secreting T cell response to L1 peptides indicating the potential for an enhanced memory response to this antigen. These results indicate that the chemical composition of aluminum adjuvants can have a profound influence on the magnitude and quality of the immune response to HPV VLP vaccines.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 35 条
  • [1] EFFECT OF PROTEIN ADSORPTION ON THE SURFACE-CHARGE CHARACTERISTICS OF ALUMINUM-CONTAINING ADJUVANTS
    ALSHAKHSHIR, R
    REGNIER, F
    WHITE, JL
    HEM, SL
    [J]. VACCINE, 1994, 12 (05) : 472 - 474
  • [2] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE
    BOSCH, FX
    MANOS, MM
    MUNOZ, N
    SHERMAN, M
    JANSEN, AM
    PETO, J
    SCHIFFMAN, MH
    MORENO, V
    KURMAN, R
    SHAH, KV
    ALIHONOU, E
    BAYO, S
    MOKHTAR, HC
    CHICAREON, S
    DAUDT, A
    DELOSRIOS, E
    GHADIRIAN, P
    KITINYA, JN
    KOULIBALY, M
    NGELANGEL, C
    TINTORE, LMP
    RIOSDALENZ, JL
    SARJADI
    SCHNEIDER, A
    TAFUR, L
    TEYSSIE, AR
    ROLON, PA
    TORROELLA, M
    TAPIA, AV
    WABINGA, HR
    ZATONSKI, W
    SYLLA, B
    VIZCAINO, P
    MAGNIN, D
    KALDOR, J
    GREER, C
    WHEELER, C
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11): : 796 - 802
  • [3] (How) do aluminium adjuvants work?
    Brewer, JM
    [J]. IMMUNOLOGY LETTERS, 2006, 102 (01) : 10 - 15
  • [4] Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus
    Christensen, ND
    Reed, CA
    Cladel, NM
    Han, R
    Kreider, JW
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (02) : 960 - 965
  • [5] Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae
    Cook, JC
    Joyce, JG
    George, HA
    Schultz, LD
    Hurni, WM
    Jansen, KU
    Hepler, RW
    Ip, C
    Lowe, RS
    Keller, PM
    Lehman, ED
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 1999, 17 (03) : 477 - 484
  • [6] In vivo absorption of aluminium-containing vaccine adjuvants using Al-26
    Flarend, RE
    Hem, SL
    White, JL
    Elmore, D
    Suckow, MA
    Rudy, AC
    Dandashli, EA
    [J]. VACCINE, 1997, 15 (12-13) : 1314 - 1318
  • [7] Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle
    Gherardi, RK
    Coquet, M
    Cherin, P
    Belec, L
    Moretto, P
    Dreyfus, PA
    Pellissier, JF
    Chariot, P
    Authier, FJ
    [J]. BRAIN, 2001, 124 : 1821 - 1831
  • [8] Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
    Giannini, Sandra L.
    Hanon, Emmanuel
    Moris, Philippe
    Van Mechelen, Marcelle
    Morel, Sandra
    Dessy, Francis
    Fourneau, Marc A.
    Colau, Brigitte
    Suzich, Joann
    Losonksy, Genevieve
    Martin, Marie-Therese
    Dubin, Gary
    Wettendorff, Martine A.
    [J]. VACCINE, 2006, 24 (33-34) : 5937 - 5949
  • [9] Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
    Harper, DM
    Franco, EL
    Wheeler, C
    Ferris, DG
    Jenkins, D
    Schuind, A
    Zahaf, T
    Innis, B
    Naud, P
    De Carvalho, NS
    Roteli-Martins, CM
    Teixeira, J
    Blatter, MM
    Korn, AP
    Quint, W
    Dubin, G
    [J]. LANCET, 2004, 364 (9447) : 1757 - 1765
  • [10] Hem S L, 1995, Pharm Biotechnol, V6, P249